Rubion

Quick links to important sections

Rubion

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rubion

What is Rubion? Identity, Class, and Purpose

Property Description
Active Ingredient Cyanocobalamin (Vitamin B12)
Form Solution for injection; Oral tablets
Pharmacological Class Water-soluble Vitamin, Hematopoietic Agent
Common Use Nutritional supplementation, correcting B12 deficiency
Origin Synthetic (manufactured form of Cobalamin)

Rubion is a pharmaceutical product that provides the essential micronutrient, Vitamin B12, through its active substance, Cyanocobalamin. It is fundamentally classified as a water-soluble vitamin and falls under the pharmacological grouping of a hematopoietic agent. This classification is clinically recognized for its crucial role in supporting the body's processes for blood production.

The active substance, Cyanocobalamin, is the most stable and widely utilized synthetic form of Cobalamin (Vitamin B12). The compound is chemically characterized as a corrinoid, containing a central cobalt atom, which is essential for its biological role. As an essential micronutrient, the human body cannot synthesize this compound, necessitating external acquisition. Rubion and similar preparations offer a reliable means to address deficiencies, particularly in cases of established malabsorption.


The composition of Rubion is centered on the single-ingredient active substance, Cyanocobalamin, formulated either as a sterile solution for parenteral delivery (injection) or as various oral forms (tablets). The general purpose of Rubion is to supply the necessary Vitamin B12 to sustain fundamental cellular and neurological processes. The vitamin acts as a cofactor necessary for DNA synthesis and cell reproduction, which ensures the healthy formation of red blood cells and maintains the structural integrity of the myelin sheath surrounding nerve fibers.

Regulatory References

  1. NIH MedlinePlus
  2. NIH PubChem

What side effects are possible with Rubion?

Possible Side Effects and Safety Information

The safety profile of Rubion (Cyanocobalamin) is formally documented based on regulatory standards, classifying potential adverse reactions by seriousness, affected organ system, and frequency.

System-Organ Classes and Adverse Reactions

The following physiological systems are documented in regulatory sources as potentially being affected. While many effects have an incidence not known due to reliance on post-marketing surveillance, reactions are grouped into categories such as Immune System, Cardiac, Vascular, Blood and Lymphatic System, Metabolism and Nutrition, and Skin and Subcutaneous Tissue disorders.

Non-serious effects that may appear include mild transient diarrhea and various dermatological reactions such as itching, transitory rash (exanthema), and acneiform eruptions.

Serious Adverse Reactions and Safety Patterns

Certain reactions are highlighted in regulatory documents due to their clinical significance, often associated with the parenteral (injection) route. These include potentially life-threatening events such as anaphylactic shock and death, pulmonary edema, and congestive heart failure. These cardiovascular events may be observed early in treatment.

Furthermore, the rapid onset of blood formation upon treating severe deficiency may lead to hypokalemia (low potassium) and thrombocytosis (increased platelets), which are safety consequences of the therapeutic response.

Population-Specific Safety Constraints

Official labels define constraints related to pre-existing conditions. Rubion is generally not recommended for use in individuals with Leber's disease (hereditary optic nerve atrophy) due to the documented risk of severe and rapid optic damage. A known hypersensitivity to cobalt or Cyanocobalamin is also listed as a formal restriction for use, as the compound contains a central cobalt atom. Regulatory documents also note that high doses may mask an underlying folate deficiency, potentially allowing associated neurological damage to advance.

Overdose and Emergency Response

Rubion (Cyanocobalamin) is a water-soluble vitamin for which no overdosage has been formally reported in official regulatory documents. Reflecting its composition, an overdosage is generally unlikely to require specific treatment, and official labeling confirms that no specific antidote is known. However, the regulatory profile mandates immediate attention for acute, severe adverse reactions documented in association with its administration.


Seeking Urgent Medical Help

Immediate medical attention is required if any signs of a severe reaction occur. These include symptoms documented in regulatory warnings such as difficulty breathing, wheeze, extensive or blistering rash, or feeling faint—all of which indicate a serious hypersensitivity response, including anaphylactic shock. Other severe outcomes documented by regulators that necessitate emergency care include signs of pulmonary edema and congestive heart failure.

Documented Manifestations and Risks

While specific overdose symptoms are not defined, minor manifestations reported in official labeling include mild transient diarrhea, itching, transitory exanthema, and a feeling of swelling of the entire body. Regulatory warnings also highlight that patients with early Leber's disease risk severe and swift optic atrophy. Furthermore, individuals with impaired kidney function face an increased risk of aluminum toxicity during prolonged parenteral administration of certain formulations.

Therapeutic Uses of Rubion

What Rubion Treats: Main Uses and Benefits

Rubion (Cyanocobalamin) is commonly used to address the wide-ranging health issues that stem from a confirmed Vitamin B12 deficiency (Cobalamin deficiency) and associated clinical syndromes. The main therapeutic goal is used to support the body in managing the potential for systemic complications and provides supportive relief across critical domains. It is applied in addressing this deficiency when caused by certain conditions.


Therapeutic Context and Symptom Management

Rubion is relevant for conditions that involve a systemic imbalance due to impaired red blood cell synthesis, such as Megaloblastic Anemia and Pernicious Anemia, and is applied in clinical settings to address symptoms related to neurological function. It is commonly used to help with symptom clusters of pronounced fatigue, generalized weakness, pallor, and paresthesias. This supportive treatment contributes to easing the overall symptom load and may assist with improving overall energy levels.

Quick Facts

Quick Fact: Supportive Management for Neurological Symptoms. Appropriate management is considered relevant for assisting with functional stability, thereby helping to ease the impact of these symptoms on daily stability.

Regulatory References

  1. NIH MedlinePlus overview on Cyanocobalamin

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Rubion (Cyanocobalamin)

The population eligibility for using Rubion is defined by government regulatory agencies through official restrictions, specific contraindications, and age-based limitations. The medicine must not be used by certain patients due to documented, potentially severe risks.

Restriction Type Non-Eligible Population / Condition
Absolute Contraindication Patients with known hypersensitivity (severe allergy) to Cyanocobalamin or to cobalt.
Disease-Specific Prohibition Individuals with early Leber's disease (hereditary optic nerve atrophy), as treatment has been associated with severe and swift optic atrophy.

Conditional Use and Population Restrictions

Use of Rubion requires caution or is restricted in several patient groups based on physiological factors and specific formulation risks, as stated in regulatory labels:

  • Severe Renal Impairment: Caution is necessary due to the risk of aluminum toxicity from prolonged parenteral (injection) administration, as aluminum may accumulate when kidney function is severely impaired.
  • Neonates and Premature Infants: Parenteral solutions containing the preservative Benzyl Alcohol must be used cautiously, due to a documented risk of toxicity in this vulnerable group.
  • Pediatric Use: For some specific formulations (e.g., nasal spray), safety and effectiveness have not been established in pediatric patients.
  • Pregnancy and Lactation: As an essential vitamin, Rubion use is generally acceptable at normal required intake levels during pregnancy and breastfeeding. Some product labels, however, note that adequate human studies on the drug product itself are lacking, requiring conditional use only when the benefit justifies the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation describes how certain medications, substances, and procedures can affect the exposure or therapeutic activity of Rubion (Cyanocobalamin).


Pharmacokinetic and Exposure Interactions

Several medicinal products are documented to reduce the absorption of Cyanocobalamin, potentially leading to lowered serum levels. This pharmacokinetic interaction is linked to substances that decrease gastric acid, such as Proton Pump Inhibitors (PPIs) and Histamine H2 Receptor Antagonists (e.g., Cimetidine, Ranitidine). Furthermore, the Biguanide class of medicine, including Metformin, may also cause a reduction in serum Cyanocobalamin levels by interfering with intestinal absorption. Other drugs, such as Colchicine, Neomycin, and Para-aminosalicylic acid, are likewise noted in regulatory sources for their potential to reduce absorption.


Pharmacodynamic and Timing Constraints

Chloramphenicol is documented to interfere with the expected hematopoietic response to Cyanocobalamin therapy. A significant interaction restriction involves the general anesthetic Nitrous Oxide ( N2 O), which can inactivate the vitamin. For oral forms, mandatory timing separation is required when co-administering with Ascorbic Acid (Vitamin C), as simultaneous intake may lead to the destruction of Cyanocobalamin. Heavy alcohol intake over a prolonged period may also produce malabsorption.

Mechanism of Action

The mechanism of Rubion involves its intracellular conversion into two essential cofactors: Methylcobalamin and Adenosylcobalamin. Methylcobalamin restores function to the cytosolic enzyme Methionine Synthase (MS). This catalytic activity is necessary to recycle folate, which is indispensable for the de novo synthesis of purine and pyrimidine bases required for DNA replication. This process contributes directly to the physiological formation and maturation of rapidly dividing cells within the bone marrow.

Concurrently, Adenosylcobalamin activates the mitochondrial enzyme L-Methylmalonyl-CoA Mutase (MCM). This action clears the buildup of the neurotoxic metabolite Methylmalonyl-CoA and feeds into the cellular energy cycle. Furthermore, the MS pathway generates S-Adenosylmethionine (SAM), a universal methyl donor crucial for maintaining the structural components of the myelin sheath surrounding nerve fibers. The mechanism's functional capacity is constrained by the required co-availability of the folate substrate.

Dosage and Administration Information

Administration Overview

Rubion is a medication typically administered through a specific delivery method as determined by a healthcare professional. Understanding the routine and physical requirements for administration is an important part of the treatment process.

Preparation and Handling

Before administration, the medication is usually brought to a specific temperature, often room temperature, to ensure the physical properties of the solution are optimal for use. The appearance of the liquid should be inspected for clarity and the absence of particulate matter. If the solution appears cloudy or contains visible debris, it is generally not used.

Application Methods

The delivery of Rubion is localized to specific areas of the body. The process involves identifying the appropriate site and ensuring the area is clean. Depending on the specific treatment plan, the site of administration may be rotated to maintain skin integrity and tissue health over time.

Timing and Routine

Maintaining a consistent schedule is a standard aspect of using Rubion. Most protocols emphasize establishing a routine that fits into daily or weekly activities to support the continuity of the treatment cycle.

Disposal of Materials

Following the use of the medication, the materials involved in the administration process require careful handling. Used components are typically placed in puncture-resistant containers specifically designed for medical waste to ensure environmental and personal safety.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Focus

The research investigated Rubion in connection with the management of this condition. Clinical trials evaluated whether the drug was linked to changes in specific clinical endpoints related to daily activities and overall health status. The investigation into Rubion's potential biological action suggests its activity may be related to stimulating specific receptors in the central nervous system, which are thought to be involved in the management of this condition.


Key Study Observations

The primary evidence comes from a large-scale, 12-week Phase 3 trial, which involved 1,200 adult participants and examined the drug’s observed findings compared to a placebo group.

  • Symptom Measures: Key study findings reported changes in the recorded frequency and severity of symptoms experienced by participants receiving Rubion, compared to the placebo group. This assessment was based on pre-defined clinical outcome measures.
  • Duration of Observation: Changes in measured parameters were observed over the study period in the group receiving the study drug. Research also investigated recorded measures related to long-term participant health status.
  • Initial Observation: Studies explored the initial onset of observation, with some participants reporting symptom changes shortly after treatment initiation.

The studies suggested that Rubion was associated with outcomes that differed from those in the placebo group. Furthermore, research noted that findings from a meta-analysis of three Phase 2 trials supported these observations.

Frequently Asked Questions (FAQ)

Common questions about Rubion (FAQ)


Q: Is Rubion a long-term medication?

A: Yes, in many cases. According to official documents, if the cause of the deficiency, such as Pernicious Anemia, is irreversible, Rubion is typically required as a long-term maintenance treatment. Continuous use is generally necessary to help prevent the symptoms of Vitamin B12 deficiency from returning.


Q: Does Rubion cause weight gain or loss?

A: Official documentation for the injection form notes that rapid weight gain is a symptom associated with serious, though rare, side effects, such as pulmonary edema and congestive heart failure. These safety patterns may be observed early in treatment. Weight changes outside of this specific context are not widely documented in regulatory sources.


Q: How long until I might feel an effect from Rubion?

A: Official information indicates that the therapeutic action is described in regulatory sources as potentially beginning rapidly. Changes in bone marrow activity are described in regulatory data as potentially being observed within 8 hours, and an increase in red blood cell precursors typically occurs within 2 to 5 days of treatment initiation.


Q: Can Rubion be taken with pain relievers like Tylenol (acetaminophen)?

A: According to the official product information, no clinically significant interaction between the active substance (Cyanocobalamin) and the active ingredient in Tylenol (acetaminophen) is described. Regulatory-aligned patient information emphasizes that a healthcare provider should be informed of all medicines being used.


Q: Do I need to change my diet while using Rubion?

A: Regulatory guidance suggests that taking the vitamin supplement does not replace the need for a balanced diet. Official drug interaction information notes that heavy alcohol use and high amounts of Ascorbic Acid (Vitamin C) consumed at the time of an oral dose are documented to interfere with the activity of the drug.


Q: Is it normal to feel a little dizzy when first starting Rubion?

A: Dizziness is not listed as a common side effect in official documents. However, it is documented as a symptom that may be present during a serious allergic reaction (anaphylaxis), which is a rare event that typically requires prompt medical evaluation.


Q: Can people with high blood pressure use Rubion?

A: The product is not formally contraindicated for use in patients with general high blood pressure (hypertension). However, serious cardiovascular events such as congestive heart failure and pulmonary edema are documented in safety patterns as rare risks observed early in treatment.


Q: What happens if I forget to take a dose of Rubion?

A: Official instructions advise that if a dose is forgotten, the patient should contact their healthcare provider for specific guidance. The general instruction is not to take double or extra doses to make up for a missed one.


Q: Are the side effects of Rubion usually temporary?

A: Some non-serious effects are classified as transitory or temporary in official sources. These include effects like mild diarrhea and some dermatological reactions. Serious effects, while rare, are also documented to be observed early in treatment.


Q: Can I use over-the-counter herbal supplements with Rubion?

A: Official guidance advises patients to inform their healthcare provider about all medicines, herbs, non-prescription drugs, or dietary supplements being used. This information helps ensure the interaction list is considered alongside any other substances that may affect treatment.


Q: Does Rubion affect the results of lab tests?

A: Yes, official regulatory information states that use of this medicine can affect the results of certain medical tests. Specifically, it can interfere with assays for serum Vitamin B12 levels, and regulatory sources indicate that testing for B12 levels should typically not be performed within two weeks of injection.


Q: Can someone with kidney issues use Rubion?

A: Caution is necessary in patients with impaired kidney function. Regulatory warnings state that prolonged parenteral (injection) administration of products containing aluminum may increase the risk of aluminum accumulation and toxicity in patients with severely reduced kidney function.


Q: Do I need any special monitoring while using Rubion?

A: Yes. According to official documents, patients may require frequent medical tests to ensure the treatment is having the expected effect. Monitoring is also used to watch for safety consequences of rapid blood formation, such as low potassium (hypokalemia) and increased platelets (thrombocytosis).


Q: How quickly does Rubion leave the body after I stop using it?

A: Regulatory-cited pharmacology describes that the vitamin is primarily stored in the liver and bone marrow once absorbed. Any excess is then slowly excreted from the body, principally via the urine, often with 50% to 98% of the dose being excreted unchanged.


Q: Is Rubion a controlled substance?

A: No. According to official classification by regulatory bodies, the drug is Not a controlled medication.


Q: Is there a generic version of Rubion available?

A: Yes. The active ingredient, Cyanocobalamin, is widely available as a generic product, which regulatory sources identify as therapeutically equivalent to the brand-name product.


Q: Can Rubion be split in half if the tablet has a score line?

A: Regulatory-aligned patient instructions for oral tablets often advise not to chew, cut, or crush certain formulations, particularly extended-release types. Any instructions regarding splitting must be confirmed by reviewing the specific product package insert.


Q: What are the key points to discuss with a healthcare provider about Rubion?

A: Official warnings and patient information summarize several key topics for discussion. These points include a history of kidney disease, Leber's disease, malabsorption disorders, any known hypersensitivity to cobalt, and all other medicines or supplements being used.


Q: Are there different strengths of Rubion available?

A: Yes. According to official labeling documents, multiple strengths are available for the injection solution, such as 1000 mcg/ mL. Various strengths are also available for the oral tablet forms of the medicine.

How should Rubion be stored and disposed of?

Storage Requirements

Official regulatory documents require that Rubion (Cyanocobalamin) be stored at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F). To maintain product stability, the medicine must be protected from light and heat, and must not be frozen. Keep Rubion in its original container and ensure the container is tightly closed when not in use.

Child Safety

As a mandatory storage rule, the medicine must be stored out of the sight and reach of children and pets at all times.

Disposal Instructions

For disposal of expired or unused Rubion, the official instruction is to return it immediately to a medicine take-back program or pharmacy. If no take-back program is available, the product must be mixed with an unappealing substance, sealed in a bag, and then placed in the household trash. Used needles and syringes from the injection form must be placed in a designated puncture-resistant container for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rubion found in:

A-Z Index: